– PhD in Human Physiology, Univ. of São Paulo, Brazil.
– Master in Exercise Physiology, Univ. of São Paulo, Brazil.
– Bachelor in Physical Education, Univ. of São Paulo, Brazil
Dr. da Silva is supported by Helse Sør-Øst RHF and Nasjonalforeningen for folkehelsen.
Dr. da Silva is the recipient of awards from the Inter-American Society of Hypertension, the International Society of Hypertension (“Osvaldo Ramos Award”) and the AHA Council for High Blood Pressure Research (“Merck New Investigator Award”), as well as Honours Degree Medal at the University of São Paulo (Brazil).
Dr. da Silva current research focuses on translational heart failure research, which covers the spectrum of preclinical and clinical investigation from cellular to molecular pathophysiology.
Early in his career, he established the concept that small gene perturbations in the renin-angiotensin system exacerbate vascular and cardiac adverse remodelling response to pathological perturbations. Later, his interest shifted towards non-coding RNA molecules and he uncovered the cardiac miRNA fingerprint in hypertrophic and dilated cardiomyopathy in patients, and in a heart failure model. He also described a multi-miRNA panel in the circulation with predictive value for future myocardial infarction, as well as circulating miRNAs which were able to discriminate different forms of heart failure.
Dr. da Silva has been taking part of international and national collaborative investigations, including a Horizon 2020 grant (OptimEx Study), a Fondation Leducq Transatlantic Network of Excellence (“MicroRNAs as Therapeutic Targets in Heart Failure”) and Stiftelsen Kristian Gerhard Jebsen Centers (“Exercise in Medicine” and “Cardiac Research”).
Presently, Dr. da Silva acts as a member of the Management Committee of the EU-CardioRNA COST Action (www.cardiorna.eu), a collaborative pan-European network of multidisciplinary partners designed to catalyze transcriptomic research in cardiovascular disease.